The ovarian cancer diagnostics market is undergoing a significant transformation as healthcare providers increasingly prioritize accurate disease identification, genetic risk assessment, and personalized treatment planning. The global Ovarian Cancer Diagnostics Market was valued at USD 1.74 billion in 2024 and is projected to reach USD 3.11 billion by 2033, expanding at a CAGR of 6.73% from 2025 to 2033. Growing investments in cancer research, advancements in biomarker discovery, and the development of artificial intelligence (AI)-enabled diagnostic platforms are creating new opportunities. The industry is gradually moving beyond conventional diagnostic approaches toward integrated solutions that combine imaging, molecular testing, genetic profiling, and liquid biopsy technologies.
Market Performance and Industry Direction
The market's growth reflects the increasing need for improved ovarian cancer detection and patient stratification. North America accounted for the largest revenue share of 34.96% in 2024, while Asia Pacific is expected to experience the fastest growth during the forecast period. The expansion is supported by rising investments in healthcare infrastructure, increasing adoption of advanced diagnostic technologies, and government-backed research initiatives.
Several factors are influencing the industry's direction:
- Biomarker discovery: Identification of genetic and molecular indicators is supporting more accurate patient classification and treatment decisions.
- AI integration: Machine learning is improving the analysis of imaging results, biomarker information, and genomic data.
- Research funding: Government investments are encouraging innovation in early detection, prevention, and precision medicine.
- Genetic testing adoption: Growing emphasis on BRCA and other genetic testing is increasing demand for molecular diagnostic services.
- Liquid biopsy development: Non-invasive testing platforms are emerging as potential tools for improving early-stage detection.
Want to Understand What’s Driving Market Growth? Ask Prism AI for research-backed insights into market size, evolving opportunities
Diagnostic Innovation Is Reshaping Clinical Practices
Traditional ovarian cancer diagnostic methods, including CA-125 blood testing, ultrasound, CT scans, and pelvic examinations, continue to play an important role in clinical practice. However, these approaches have limitations, particularly when identifying the disease at an early stage. Consequently, healthcare providers and researchers are exploring more comprehensive diagnostic strategies.
One important development is the identification of PPP2R1A mutations as a predictive biomarker in ovarian clear cell carcinoma. Research published in July 2025 by MD Anderson Cancer Center highlighted its association with improved survival outcomes among patients receiving immunotherapy. This finding strengthens the importance of immunogenomic testing and genetic profiling in treatment selection.
AI-powered diagnostic platforms are also gaining attention. In August 2025, AOA Dx published research demonstrating the performance of its multi-omic blood test. The platform combines lipid, ganglioside, and protein biomarkers with machine learning. It achieved an area under the curve (AUC) of 93% for all disease stages and 91% for early-stage ovarian cancer in training cohorts. Results from independent real-world cohorts reached 92% and 88%, respectively.
These developments indicate a growing shift toward diagnostic solutions that combine multiple biological indicators instead of relying on individual biomarkers.
Understanding the Market Through Its Major Segments
The market is categorized by cancer type, diagnosis method, and end use. Each category reflects a different aspect of clinical demand and technology adoption.
Cancer type: Epithelial tumors remain the dominant category
The epithelial tumor segment accounted for 90.33% of market revenue in 2024. Epithelial ovarian tumors represent the most common form of ovarian cancer, creating substantial demand for diagnostic techniques capable of identifying and characterizing these tumors. Stromal cell tumors also present opportunities for advanced imaging, molecular diagnostics, and genetic profiling.
Download a free sample report or claim your copy of this full market intelligence report
Diagnosis method: Imaging maintains its leading position
Imaging represented 31.95% of the market in 2024. Transvaginal ultrasound continues to serve as an important first-line diagnostic method because of its accessibility and cost-effectiveness. Structured reporting systems such as O-RADS are helping improve consistency in ultrasound and MRI interpretation.
CT scans remain relevant for staging and surgical planning, while MRI and PET/CT support the assessment of metastases and recurrence. Molecular imaging is also expanding the capabilities of surgical diagnosis. In November 2021, the FDA approved Cytalux (pafolacianine), an imaging agent designed to help surgeons identify ovarian cancer lesions during surgery. The technology identified additional cancerous lesions in 26.9% of patients that were not detected through conventional methods.
End use: Hospital laboratories lead adoption
Hospital laboratories held the largest revenue share of 40.49% in 2024. Hospitals increasingly collaborate with diagnostic companies, research institutions, and pharmaceutical organizations to strengthen testing capabilities. Academic medical centers and specialized cancer institutes also support the adoption of advanced molecular testing, next-generation sequencing, and liquid biopsy platforms.
Research Funding and Access Gaps Influence Demand
Government support is an important contributor to diagnostic innovation. In April 2025, the U.S. Department of Defense announced USD 650 million in appropriations for its Congressionally Directed Medical Research Programs, including dedicated support for the Ovarian Cancer Research Program. The FY25 initiative supports research in early detection, prevention, survivorship, and precision medicine.
However, access to testing remains uneven. A March 2025 report by the Ovarian Cancer Research Alliance and Komodo Health indicated that nearly half of women with ovarian cancer were not receiving genetic testing despite universal guidelines. Testing rates were particularly low among women older than 65 and those with public insurance, falling below 40%.
These disparities create a need for better patient awareness, accessible diagnostic services, and improved healthcare navigation. Digital platforms and patient-support initiatives are helping connect individuals with gynecologic oncology specialists and clinical trial resources.
Regional Market Landscape
North America maintained its leading position in 2024, supported by high healthcare expenditure, advanced diagnostic infrastructure, and growing adoption of genetic testing and molecular imaging. In the U.S., MRI, CT scans, CA-125, HE4, and BRCA testing contribute to the diagnostic ecosystem. Federal research programs are also supporting biomarker discovery and AI-enabled testing.
Europe demonstrates steady demand, supported by BRCA and HRD testing, established clinical networks, and genomic medicine initiatives. Germany has a strong position in companion diagnostics, while the UK is focusing on universal germline testing, opportunistic salpingectomy, and liquid biopsy validation. Differences in reimbursement policies and cost-containment measures continue to influence adoption across the region.
Asia Pacific is the fastest-growing regional market. Increasing cancer incidence, government-backed healthcare initiatives, and investments in diagnostic infrastructure are supporting expansion. China is increasing molecular testing capacity, while Japan benefits from imaging innovation, BRCA testing coverage, and a strong clinical trial ecosystem. However, affordability and differences in urban and rural healthcare access remain challenges.
In Latin America, Brazil is emerging as an important market for molecular testing and diagnostic laboratory investments. Across the Middle East and Africa, adoption remains at an earlier stage, with diagnostic infrastructure concentrated in urban areas. Investments in genomic testing and cancer centers in Saudi Arabia and the UAE are supporting gradual market development.
Future Market Outlook
The future development of the ovarian cancer diagnostics market will depend on the successful integration of genetic testing, AI-powered liquid biopsies, advanced imaging, and multi-omic technologies. International patient-data initiatives and research collaborations may further support biomarker validation and real-world evidence generation.
Although testing disparities, reimbursement limitations, and the lack of validated early screening tools remain challenges, continued investment in precision diagnostics is creating opportunities for market expansion. The combination of improved diagnostic accuracy, patient-centered testing approaches, and research-driven innovation is expected to shape the industry's growth through 2033.
Explore Our Research & Intelligence Solutions
U.S. Healthcare Facility Intelligence: Make Better Decisions with Comprehensive Data – Explore the Platform